Interpace Effecting a 1-for-10 Reverse Stock Split

Dec 28, 2016

|

NEW YORK (GenomeWeb) – Interpace will effect a 1-for-10 reverse stock split in a bid to keep its shares listed on the Nasdaq, the company announced after the close of the market on Wednesday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Interpace Effecting a 1-for-10 Reverse Stock Split

To read the full story....

Breaking News

FDA Issues EUA for Adaptive Biotechnologies COVID-19 T-Cell Response Test

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

German Stores to Begin Selling COVID-19 Rapid Antigen Tests for Home Use

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

DermTech Q4 Revenues Up 31 Percent

What's Popular?

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

OraSure Technologies Updates Plan for SARS-CoV-2 Antigen Self-Test

C2i Genomics Acquires Sequencing Lab QNA Dx

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships